Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine - Top-Institutions - MDSpire

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • By

  • Spyros Chalkias

  • Antionette Pragalos

  • Adebayo Akinsola

  • Gary Berman

  • Madhavi Ampajwala

  • Jay Meyer

  • Lorraine Schoch

  • Wen Zhou

  • Yamuna D Paila

  • Weiping Deng

  • Jing Feng

  • Elizabeth de Windt

  • Darin Edwards

  • Jacqueline Miller

  • Rituparna Das

  • January 10, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID)
    National Institute of Allergy and Infectious Diseases (NIAID)

    Bethesda, MD

    Key Differentiators

    • Infectious Disease
    • Vaccine Development
    • Immunology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Disease
    • Immunology
    • Vaccine Research

  • #3

    Vaccine Research Center, National Institutes of Health (NIH)
    Vaccine Research Center, National Institutes of Health (NIH)

    Bethesda, MD

    Key Differentiators

    • Vaccine Development
    • Immunology
    • Infectious Diseases

  • #4

    Massachusetts General Hospital, Harvard Medical School
    Massachusetts General Hospital, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Infectious Disease
    • Clinical Trials
    • Immunology

  • #5

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Infectious Disease
    • Vaccine Research
    • Immunology

Original Source(s)

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • by Spyros Chalkias, Antionette Pragalos, Adebayo Akinsola, Gary Berman, Madhavi Ampajwala, Jay Meyer, Lorraine Schoch, Wen Zhou, Yamuna D Paila, Weiping Deng, Jing Feng, Elizabeth de Windt, Darin Edwards, Jacqueline Miller, Rituparna Das

  • January 10, 2025

Related Content

Assessing PEPFAR’s Health Spillover Effects Beyond HIV: An Update

Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis

Increased anti-nucleocapsid secretory IgA and consumption of complement component 3 in post-COVID syndrome patients